Abstract:
Objective To assess the effect and safety of the Newcastle disease virus in chemotherapy for patients with stages ⅢB and Ⅳ non-small cell lung cancer (NSCLC).
Methods A total of 146 patients with advanced NSCLC were enrolled in this study. The patients were evenly randomized to experimental and control groups. Newcastle disease virus combined with the NP regimen (vinorelbine and carboplatin, n=73) was given to the experimental group, and NP regimen only (n=73) was given to the control group. The chemotherapy was performed for four cycles every 28 days, and the therapeutic efficacy was evaluated every 2 weeks. The following indicators were observed: levels of hemoglobin, white blood cell, platelet, and T cell subpopulation in the blood, as well as short-term efficacy, adverse effects, and quality of life.
Results The response rate in the experimental and control groups were 50.68% and 41.10%, respectively (P < 0.05). The Karnofsky performance score were higher in the experimental group than in the control group (P < 0.01). Gastrointestinal reactions, impairment of renal functions, nausea, and vomiting, diarrhea, and myelosuppression were alleviated in the experimental group compared with the control group; the difference was significant (P < 0.05). The CD4/CD8 ratio increased in the experimental group (P < 0.05) but decreased in the control group (P > 0.05).
Conclusion The Newcastle disease virus combined with the NP regimen shows a better therapeutic effect, reduces the adverse effects of chemotherapy, and improves the quality of life of patients with stages Ⅲ and Ⅳ NSCLC.